We use cookies to display personalized content, analyze site traffic, provide recommendations, and ensure you have a great browsing experience. By continuing to use our site, you consent to our use of cookies. Privacy Policy.
FDA medical device compliance is not a single process. The pathway that applies to your device depends on its classification, intended use, and risk profile, and getting that determination right shapes every decision that follows. Since 2007, QSS has guided domestic and international manufacturers through FDA regulatory requirements across every device category.
FDA medical device requirements vary significantly by device classification. Class I devices face the lightest regulatory burden. Class II devices, the largest category, typically require 510(k) clearance before reaching the U.S. market. Class III devices, those that sustain or support life or carry the highest risk, require Premarket Approval. Determining where your device falls is the first and most consequential step in any U.S. market entry plan.
Separate from premarket submissions, FDA establishment registration and device listing through FURLS is required for every facility that manufactures, imports, or distributes devices in the United States. This obligation applies to domestic and foreign establishments alike and must be renewed annually. For international manufacturers, designation of a U.S. Agent is also required. These requirements run in parallel with submission preparation and are not optional regardless of device class.
The regulatory picture does not end at clearance or approval. Post-market obligations, including adverse event reporting, device modification assessments, and post-approval study requirements for PMA holders, are active compliance responsibilities. Companies that treat FDA compliance as a one-time event rather than an ongoing program expose themselves to enforcement risk and market access disruption.
|
Device Class
|
Submission Type
|
Pathway
|
Typical Timeline
|
|---|---|---|---|
|
Class I (most)
|
Exempt
|
Facility registration + listing only
|
Immediate upon registration
|
|
Class II
|
510(K)
|
Demonstrate substantial equivalence to predicate
|
90-day FDA review (from acceptance)
|
|
Class II (novel)
|
De Novo
|
New low-to-moderate risk device, no predicate
|
12+ months
|
|
Class III
|
PMA
|
Full scientific review; clinical data required
|
180-day statutory review + clinical stage
|
|
IVD Devices
|
510(k) or PMA
|
510(k) for most; PMA if Class III IVD
|
Same as Class II/III above
|
|
SaMD
|
510(k) or De Novo
|
Depends on intended use and risk category
|
Varies by classification
|
For most Class II medical devices, FDA 510(k) clearance is the required pathway to U.S. market entry. QSS supports manufacturers from predicate selection and technical documentation through FDA review and deficiency response.
All domestic and foreign establishments must register with the FDA and list their devices through the FURLS system before distributing in the United States. QSS guides manufacturers through initial registration, device listing, annual renewal, and U.S. Agent designation.
IVD devices face a distinct regulatory framework that evaluates both substantial equivalence and analytical performance. QSS supports IVD manufacturers through assessment, 510(k) submission, and post-market compliance.
Software that performs a medical function independently is subject to FDA oversight under the SaMD framework. QSS advises on classification, submission requirements, cybersecurity, and post-market obligations.
Class III devices that cannot rely on substantial equivalence require PMA, the most rigorous FDA review pathway. QSS supports through pathway assessment, application preparation, clinical study design, FDA review management, and post-approval compliance.
The pathway depends on your device’s classification. FDA classifies devices into three risk-based categories. Class I devices face minimal regulatory requirements and most are exempt from premarket review. Class II devices, the broadest category, typically require 510(k) clearance to demonstrate substantial equivalence to a predicate device already on the market. Class III devices, which carry the highest risk or lack a valid predicate, require Premarket Approval. Some novel low-to-moderate risk devices without a predicate may qualify for De Novo classification. A regulatory pathway assessment, using your device’s intended use, design, and risk profile, is the necessary first step before any submission work begins.
Most medical devices require either 510(k) clearance or Premarket Approval before they can be legally marketed in the U.S. Some Class I devices are exempt from premarket review but still require establishment registration and device listing. The specific requirement depends on your device classification and intended use. International manufacturers are subject to the same requirements as U.S.-based companies, including FDA establishment registration and, in most cases, designation of a U.S. Agent before distribution begins.
Yes, they are separate obligations. FDA establishment registration identifies your facility as a manufacturer, importer, or distributor of medical devices. Device listing identifies the specific products your establishment makes or distributes. Both must be completed before you can legally market a device in the United States and must be renewed annually. They run in parallel with, but are independent of, any premarket submission such as a 510(k) or PMA. Foreign establishments must also designate a U.S. Agent as part of the FURLS registration process.
Yes. International manufacturers can market medical devices in the United States, but all FDA requirements apply regardless of where the device is manufactured. This includes device classification, the applicable premarket submission, FDA establishment registration through FURLS, device listing, and designation of a U.S. Agent. Labelling must also comply with FDA requirements, which differ from other regulatory frameworks. Understanding the full compliance picture before beginning the U.S. market entry process is the most effective way to avoid delays.
Timelines vary by pathway and device complexity. For 510(k) submissions, FDA’s review target is 90 days from acceptance, though total elapsed time is typically longer when accounting for acceptance review and any Additional Information requests. PMA applications have a 180-day statutory review period, but the full timeline from pre-submission through approval typically spans multiple years, including clinical study execution. IVD and SaMD submissions follow similar 510(k) timelines but have pathway-specific documentation requirements that affect preparation time. Submissions built to FDA’s current standards move through review with fewer interruptions.
Post-market compliance obligations begin the moment your device is cleared or approved. These include adverse event reporting under FDA’s Medical Device Reporting (MDR) requirements, annual establishment registration renewal, and assessment of any device or labelling modifications to determine whether a new submission is required. PMA holders carry additional obligations, including post-approval study reporting and annual PMA reports. Building a post-market compliance program from day one, rather than addressing obligations reactively, is the most reliable approach to maintaining FDA standing over time.
Many manufacturers pursue Health Canada Medical Device licensing and FDA clearance or approval simultaneously. QSS guides companies through both regulatory pathways, helping them manage parallel submissions without losing momentum on either side.
Talk to a specialist about your IVD device registration pathway, whether you are determining classification for the first time or preparing a 510(k) for the U.S. market.